** Shares of Emyria EMD.AX rise 2.9% to A$0.036, their highest levels since Dec 11

** The early-stage drug developer announces positive interim analysis results of its MDMA-assisted therapy programme for Post Traumatic Stress Disorder (PTSD)

** Co says therapy programme clinically reduces PTSD symptoms in first eight patients

** Stock rose as much as 14.3% to A$0.040 earlier in the day, marking its biggest intraday gain since Jan 22

** About 1.3 mln shares change hands, 6.9 times the 30-day average of 189,038

** Stock has risen 5.9% YTD, including current session's moves

(Reporting by Manasi Dasa Sundeep in Bengaluru)

((Manasi.DasaSundeep@thomsonreuters.com;))